Core Insights - MediPharm Labs Corp. has commenced production of novel cannabis metered dose inhalers for the EU and the UK, adhering to global pharmaceutical standards and distributed by Blackpoint Limited [1][4] - The inhaler offers a smoke-free option for patients, delivering precise doses of cannabis active pharmaceutical ingredients (API) without combustion or heating [2][8] - The company plans to launch these inhalers in Australia, the EU, and the UK in Q3 of 2025, following their introduction in the Canadian market [3] Company Overview - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and products, utilizing a GMP-certified facility [6] - The company holds a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American company with a commercial-scale GMP license for extracting multiple natural cannabinoids [7] Market Strategy - MediPharm Labs is the exclusive supplier of the cannabis metered dose inhaler to Blackpoint, which will leverage its distribution networks in the EU and the UK [8] - The European medicinal cannabis market is projected to be worth €834 million in 2024, indicating significant growth potential for MediPharm's products [8][12] Product Features - The metered dose inhaler is designed for medical applications, providing a discreet and effective delivery method similar to traditional asthma inhalers [8] - The product is manufactured under stringent GMP standards, ensuring high quality and safety for medical use [8]